8-K: Aimei Health Technology Extends Business Combination Deadline to July 6, 2025, Secures $150,000 Promissory Note

Aimei Health Technology Co., Ltd. has announced a one-month extension to its business combination deadline, now set for July 6, 2025, funded by a $150,000 unsecured promissory note from its sponsor and target company.

Summary

• Aimei Health Technology Co., Ltd. (the "Company") has extended the period to consummate its initial business combination by one month, from June 6, 2025, to July 6, 2025.
• This extension is the seventh of up to 12 permitted under the Company's Amended and Restated Articles of Association.
• An aggregate of $150,000 (the "Extension Payment") was deposited into the Company's trust account for its public shareholders to enable this extension.
• In connection with the Extension, the Company issued an unsecured promissory note for $150,000 (the "Promissory Note") to Aimei Health Ltd (the "Sponsor") and United Hydrogen Group Inc. ("United Hydrogen").
• The $150,000 was equally divided between the Payees, with each contributing $75,000.
• The Promissory Note does not bear interest and its principal becomes due and payable upon the consummation of a business combination with United Hydrogen.
• The Payees have the right, but not the obligation, to convert the Promissory Note, in whole or in part, into private units of the Company at a price of $10.00 per unit.
• Each private unit consists of one ordinary share and one right to receive one-fifth (1/5) of one ordinary share of the Company, convertible immediately prior to the consummation of the Business Combination.
• The Payees have waived any claim to the funds held in the Company's trust account.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the extension provides necessary time, it also highlights the ongoing challenges in completing the business combination, which is a common occurrence for SPACs. The funding from the sponsor and target is a positive sign of commitment, but the repeated extensions introduce uncertainty.

Positives

• The extension provides the Company with an additional month to complete its initial business combination, indicating ongoing efforts to finalize the transaction.
• The funding for the extension, provided by the Sponsor and the target company, United Hydrogen Group Inc., demonstrates continued commitment from key parties to the potential business combination.

Negatives

• This is the seventh extension, suggesting persistent challenges or delays in consummating the business combination.
• The Company continues to rely on its Sponsor and the target company for funding extensions, which could indicate limited alternative financing options.
• The conversion feature of the promissory note could lead to dilution for existing shareholders if exercised.

Risks

• Risk of failure to consummate the business combination with United Hydrogen Group Inc. by the new termination date of July 6, 2025.
• Continued reliance on the Sponsor and United Hydrogen Group Inc. for financial support and extensions.
• Potential dilution for existing shareholders if the promissory note is converted into private units prior to the business combination.
• The Company's ability to meet its obligations under the promissory note is contingent on the successful consummation of the business combination.

Future Outlook

The Company's immediate future outlook is focused on successfully consummating its business combination with United Hydrogen Group Inc. by the newly extended deadline of July 6, 2025. The issuance of the promissory note and the extension indicate a continued commitment to this transaction.

Management Comments

• Junheng Xie, Chief Executive Officer and Director (Principal Executive Officer) of Aimei Health Technology Co., Ltd., signed the report on behalf of the registrant.

Industry Context

This filing is typical for Special Purpose Acquisition Companies (SPACs) that require additional time to identify and complete a de-SPAC transaction. Extensions are common in the SPAC lifecycle, especially in a challenging market environment, as companies navigate complex merger processes and regulatory requirements. The involvement of the target company in funding the extension is a notable aspect, indicating a strong alignment of interests.

Related Party Transactions

• The Company issued an unsecured promissory note to Aimei Health Ltd, which is the Company's Sponsor, and United Hydrogen Group Inc., which is the target company for the business combination. This constitutes a related party transaction as the Sponsor is a key stakeholder and United Hydrogen is the counterparty to the intended merger.

Stakeholder Impact

• Shareholders: Face continued uncertainty regarding the business combination and potential dilution if the promissory note is converted into equity.
• Sponsor (Aimei Health Ltd): Provides additional funding, demonstrating continued commitment, and gains potential conversion rights.
• Target Company (United Hydrogen Group Inc.): Contributes to the extension funding, indicating its continued interest in the business combination, and gains potential conversion rights.

Next Steps

• The Company's primary next step is to consummate its business combination with United Hydrogen Group Inc. by the new termination date of July 6, 2025.

Key Dates

Recommendation

Keywords

SPAC, business combination, extension, promissory note, Aimei Health Technology, United Hydrogen Group, SEC filing, trust account, corporate governance, financial obligation